Abstract:Targeted therapeutics is used as an alternative treatment of non-small cell lung cancer (NSCLC); however, treatment effect is far from being satisfactory, and therefore identification of new targets is needed. We have previously shown that metuzumab inhibit tumor growth in vivo. The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. Our results demonstrate that, in comparison to single agent metuzumab or GP treated cells, metuzumab combined with GP display inhibitory effects on tumor growth. Furthermore, we found that metuzumab elevated the sensitivity of cell lines to gemcitabine, which was identified by MTT assay. Flow cytometric analysis showed that metuzumab combined with gemcitabine (GEM) treatment led to an obvious G1 arrest and an elevated apoptosis in A549, NCI-H460 and NCI-H520 cells. Western blot analysis also demonstrated a significantly reduced level of cyclin D1, Bcl-2, and an obviously increase level of Bax and full-length caspase-3 in A549, NCI-H460 and NCI-H520 cells treated with metuzumab/gemcitabine combination in comparison with single agent treated cells. In addition, metuzumab/gemcitabine treated A549, NCI-H460 and NCI-H520 cells also demonstrated a significantly increase in deoxycytidine kinase (dCK) protein level compared with single agent metuzumab or gemcitabine treated cells. Xenograft models also demonstrated that this metuzumab/gemcitabine combination led to upregulation of dCK. Taken together, the mechanisms of metuzumab combined with GP repress tumor growth were that the combined treatment significantly inhibited the tumor cell proliferation, apoptosis and cell cycle in vitro and in vivo and at least partially by induction of dCK expression. Our results suggested that metuzumab could significantly enhance chemosensitivity of human NSCLC cells to gemcitabine. Metuzumab/gemcitabine combination treatment may be a potentially useful therapeutic regimen for NSCLC patients.

Effect of Met in combination with GEM on human pancreatic cancer cell line CFPAC-1

Inhibitory Effect of Metformin Combined with Gemcitabine on Pancreatic Cancer Cells in Vitro and in Vivo.

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Effect of metformin on proliferation and apoptosis in human pancreatic cancer cell line CFPAC-1

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Effect of Gemcitabine on Proliferation, Apoptosis and Polo-Like Kinase-1 Expression of Pancreatic Cancer Cell Line AsPC-1

Efficacy of Gemcetabine and LY294002 on the Growth of Human Pancreatic Cancer Cell Lines BxPc-3 and MiaPaCa-2

The effect of Gemcitabine on pancreatic cancer PC-2 cells growth and gene expression

Effect of cerulenin combined with gemcitabine on proliferation and apoptosis in human pancreatic cell line BxPC3

N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.

The Combination Effect of Gemcitabine with Mitomycin on Human Lung Cancer A549 Cell Line in Vitro

Synergistic Effect of Curcumin plus Gemcitabine Combination Therapy on the Proliferation, Apoptosis and Cancer Stem Cell Phenotype of Pancreatic Cancer Cells

Combined Effect of 125I and Gemcitabine on PANC-1 Cells: Cellular Apoptosis and Cell Cycle Arrest.

Metuzumab Enhanced Chemosensitivity and Apoptosis in Non-Small Cell Lung Carcinoma.

The Preliminary Research of the Effect of Gum Mastic Combined with Gemcitabine in Human Pancreatic Carcinoma BxPc-3 Cells and Its Mechanism

Effect of Gemzar Combined with Electron Ray on Tumor Apoptosis in Nude Mice Xenograft of Human Pancreatic Carcinoma

(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells

Meta-analysis on Inoperable Pancreatic Cancer: a Comparison Between Gemcitabine-Based Combination Therapy and Gemcitabine Alone.

Gemcitabine Sensitizes Pancreatic Cancer Cells to the Ctls Antitumor Response Induced by Bcg-Stimulated Dendritic Cells Via A Fas-Dependent Pathway

Metformin Potentiates the Anticancer Activities of Gemcitabine and Cisplatin Against Cholangiocarcinoma Cells in Vitro and in Vivo

A Comparison Between Gemcitabine-Based Combination Chemotherapy and Gemcitabine Alone on Advanced Pancreatic Cancer:A Meta-analysis in Phase III Clinical Trials